General Information of Drug (ID: DMZQ8YV)

Drug Name
PD-0173958 Drug Info
Synonyms
PD173958; AC1NS9BT; PD-0173958; SCHEMBL1335649; CHEMBL578006; BDBM6570; 6-(2,6-dichlorophenyl)-2-(4-ethoxyanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 2-[(4-Ethoxyphenyl)amino]-8-methyl-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidine-7(8H)-one
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5330525
TTD Drug ID
DMZQ8YV

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor receptor 1 (FGFR1) TTRLW2X FGFR1_HUMAN Inhibitor [1]
LCK tyrosine protein kinase (LCK) TT860QF LCK_HUMAN Inhibitor [1]
Platelet-derived growth factor receptor alpha (PDGFRA) TT8FYO9 PGFRA_HUMAN Inhibitor [1]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Inhibitor [1]
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Fibroblast growth factor receptor 1 (FGFR1) DTT FGFR1 5.32 6.548 5.908 6.126
Platelet-derived growth factor receptor beta (PDGFRB) DTT PDGFRB 6.43 6.333 6.671 5.97
Platelet-derived growth factor receptor alpha (PDGFRA) DTT PDGFRA 6.189 7.636 7.84 7.086
LCK tyrosine protein kinase (LCK) DTT LCK 5.2 4.443 4.53 6.325
Proto-oncogene c-Src (SRC) DTT SRC 2.907 3.35 3.498 4.75
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Fibroblast growth factor receptor 1 (FGFR1) DTT FGFR1 4.79E-02 -0.03 -0.15
Platelet-derived growth factor receptor beta (PDGFRB) DTT PDGFRB 5.35E-10 0.36 0.89
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.